---
title: "The cellular immunotherapy sector has seen a short-term surge, with Staidson BioPharm rising over 10%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/242300903.md"
description: "The cell immunotherapy sector saw a short-term surge, with Staidson BioPharm rising over 10%, followed by XUERONG, RemeGen, Kingmed Diagnostics, Lummy, and Heyuan Bio"
datetime: "2025-05-29T01:37:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/242300903.md)
  - [en](https://longbridge.com/en/news/242300903.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/242300903.md)
---

# The cellular immunotherapy sector has seen a short-term surge, with Staidson BioPharm rising over 10%

The cell immunotherapy sector saw a short-term surge, with Staidson BioPharm rising over 10%, followed by XUERONG, RemeGen, Kingmed Diagnostics, Lummy, and Heyuan Bio

### Related Stocks

- [300006.CN](https://longbridge.com/en/quote/300006.CN.md)
- [300511.CN](https://longbridge.com/en/quote/300511.CN.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [603882.CN](https://longbridge.com/en/quote/603882.CN.md)
- [300204.CN](https://longbridge.com/en/quote/300204.CN.md)
- [688238.CN](https://longbridge.com/en/quote/688238.CN.md)

## Related News & Research

- [Why billionaire Stanley Druckenmiller and Wall Street analysts love this biotech stock](https://longbridge.com/en/news/294613624.md)
- [EXCLUSIVE: JPMorgan Sees US ETF Market Reaching $25 Trillion by 2030 — 'We Have Yet to See Any Signs of Moderation'](https://longbridge.com/en/news/294640815.md)
- [ISM manufacturing gauge hits highest since May 2022](https://longbridge.com/en/news/294711871.md)
- [REG - Revolution Beauty Gp - Block Listing Six Monthly Return](https://longbridge.com/en/news/294677831.md)
- [CFPB gets another acting director as OMB's Vought exits](https://longbridge.com/en/news/294716378.md)